Domain Associates
Venture capitalPrinceton · Seed–Growth · 11 people tracked
Also known as DOMAIN ASSOCIATES, LLC
Investment thesis
Domain Associates focuses on the biotech sector, having pioneered the first venture capital fund dedicated to biotech and managing multiple subsequent biotech-focused venture funds.
Source: firm website, verified Aug 25, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 19 of 20 portfolio companiesBiotech ×17Healthtech ×9Medical Devices ×4Deep Tech ×3Digital Health ×3AI & Machine Learning ×2Consumer ×1Direct to Consumer ×1
HQs:United States×18
Investments · 20 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12020 · 12015 · 72014 · 111 dated
Aldeyra develops medicines for immune-mediated diseases, with product candidates aimed at inhibiting inflammatory cells linked to ocular and systemic conditions.
BiotechMedical DevicesLexington, US
Todd C. Brady(Executive Officer, Director)Stephen Tulipano(Executive Officer)Scott L. Young(Executive Officer)
BoardJesse I. Treu(Director)inBen Bronstein(Director)Gary Phillips(Director)
Board seatJesse Treu· per SEC Form D · $18.4M raise · filed Jan 2015
BiotechSan Diego, US
Han Cao(Executive Officer)Gulsen Kama(Executive Officer)Mark Oldakowski(Executive Officer)Jonathan Dixon(Executive Officer)R. Erik Holmlin(Executive Officer, Director)Alka Chaubey(Executive Officer)
Board seatBrian Halak· per SEC Form D · $68.4M raise · filed Jan 2015
BiotechSan Diego, US
Ivy Zhang(Executive Officer)Saundra Pelletier(Executive Officer, Director)Kelly Culwell(Executive Officer)Justin J. File(Executive Officer)Alexander A. Fitzpatrick(Executive Officer)Russell Barrans(Executive Officer)
Board seatKim Kamdar· per SEC Form D · $25M raise · filed May 2020
Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.
BiotechDigital HealthFemTechHealthtechSalt Lake City, US
Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)Gregory C. Critchfield(Executive Officer, Director)Andrew A. Sauter(Executive Officer)Richard L. Novak(Director)
BoardMansoor Mirza(Director)
Co-investorsaMoonExcelestar VenturesOUP (Osage University Partners)UpStart VenturesVivo CapitalCatalyst Health Ventures
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedEDB InvestmentsSection 32Frazier Life Sciences+3 more
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.
BiotechDigital HealthMedical DevicesSan Diego, US
Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)
Co-investorsDns CapitalGreatPoint VenturesWittington VenturesMedical Excellence CapitalOS Fund
BiotechSan Mateo, US
Anthony Ford(Executive Officer)Michael Kitt(Executive Officer)Kathleen Sereda Glaub(Executive Officer, Director)
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Board seatJesse Treu· per SEC Form D · $55M raise · filed Jul 2015
Co-investorsPappas CapitalThird Rock Ventures
BiotechDurham, US
Bernice Kuca(Executive Officer)Mathers P. Thomas(Executive Officer, Director)Nadia Rupniak(Executive Officer)Timothy C. Gupton(Executive Officer)
BoardJesse I. Treu(Director)inRichard J. Markham(Director)
Board seatJesse Treu· per SEC Form D · $37.1M raise · filed Jan 2015
Co-investorsPappas CapitalTVM Capital
BiotechBellevue, US
Michael Gertner(Executive Officer, Director)
BoardLouis Cannon(Director)Christopher Shen(Director)Immanuel Thangaraj(Director)Henry A. Plain, Jr.(Director)
Board seatBrian Halak· per SEC Form D · $22.4M raise · filed Sep 2015
Co-investorsLightstone Ventures
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)Joseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardBrian H. Dovey(Director)in
Board seatBrian DoveyEckard Weber· per SEC Form D · $90M raise · filed Sep 2015
Co-investorsCross Creek AdvisorsNew Enterprise Associates (NEA)Sofinnova VenturesDomain Partners
HealthtechDuluth, US
Anthony V. Lando(Executive Officer, Director)Todd Meyer(Executive Officer)Dilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Todd Brady(Director)Dilip Paithankar(Executive Officer)
Board seatJesse Treu· per SEC Form D · $15M raise · filed Sep 2019
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Board seatBrian Halak· per SEC Form D · $125.5M raise · filed Jun 2026
Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo Capital+1 more
BiotechCarlsbad, US
Thomas M. Estok(Executive Officer, Director)Tracy Parrott(Executive Officer)Dennis Bilski(Executive Officer)
BoardEvgeny Zaytsev, M.D.(Director)Alain Schreiber(Director)
Board seatKim KamdarEckard Weber· per SEC Form D · $1.2M raise · filed Jul 2015
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)Gregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)Axel Scherer(Director)
BoardJustin Klein(Director)in
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Partners+2 more
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)Theodore Ebel(Executive Officer)Lynelle Lynch(Director)Howard D. Palefsky(Director)Brian H. Dovey(Director)
Co-investors1315 CapitalAisling CapitalHealthCare Ventures, LLCLongwood FundRoundTable Healthcare PartnersSplit Rock Partners
GenVault operates a GxP-compliant biorepository providing secure, temperature-controlled storage, sample management, and lab relocation services for biological, clinical, and biopharmaceutical materials.
BiotechHealthtechLogistics & Supply Chain
Co-investorsCross Creek Advisors
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.
AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US
Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)PAUL GAROFOLO(Executive Officer, Director)Nick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))
BoardGEOFFREY GLASS(Director)DAVID JOHNSTON(Director)
Co-investorsArtis VenturesAbstract VenturesHemisphere Ventures LLCLongitude CapitalStarlight Ventures
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesFlare Capital Partners+1 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
Co-investorsARCH Venture PartnersDecheng CapitalALTITUDE LIFE SCIENCE VENTURESHillhouse CapitalNan Fung Life Sciences
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Marc N. Casper(Executive Officer, Director)Andrew J. Thomson(Executive Officer)William G. Parrett(Director)Peter M. Wilver(Executive Officer)Seth H. Hoogasian(Executive Officer)Alan J. Malus(Executive Officer)
Co-investorsARCH Venture PartnersBayMed Venture PartnersCross Creek AdvisorsExcel Venture ManagementHeran PartnersOak HC/FT+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
IPOs and acquisitions across the tracked portfolioAldeyra TherapeuticsNASDAQ: ALDXBionano GenomicsNASDAQ: BNGOEvofem BiosciencesOTC: EVFMSera PrognosticsNASDAQ: SERAGenVaultacq. by Thermo Fisher Scientific
Portfolio news
latest coverage across their companiesSera Prognostics · news.alphastreet.com · Aug 20, 2026
Bionano Genomics · stocktitan.net · Aug 14, 2026
SonoThera · statnews.com · Jul 17, 2026
Colorescience · latimes.com · Feb 25, 2026
Omniome · sif.gatesfoundation.org · Feb 3, 2026
Aspen Neuroscience · longevity.technology · Nov 24, 2025
Evofem Biosciences · investing.com · Apr 14, 2025
Fund performance · per public LP disclosures
as of Mar 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Domain Excelsior Fund, LPLPs: Empire State Development – New York Ventures | 2022 | — | — | 12.49x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does Domain Associates invest at?
- Domain Associates invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Domain Associates's typical check size?
- Domain Associates typically writes checks of $200K – $15M.
- What sectors does Domain Associates focus on?
- Domain Associates focuses on Biotech.
- Where is Domain Associates located?
- Domain Associates is headquartered in Princeton, US.
Co-investors · 35
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
Unknown Ventures is a venture studio based in Austin that provides funding and operational support to early-stage startups at the pre-seed to Series A stage. The firm backs founders seeking to create innovative solutions that improve human experience.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Meritech Capital Partners is a venture capital firm, founded in 1999, that invests in market-leading technology companies, having backed 200+ investments with 60+ IPOs.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
▶23 more co-investors
Polaris PartnersWildcat Venture PartnersVersant VenturesForbionJohnson & Johnson Innovation – JJDCDeerfield Management CompanyAbingworthStanford UniversityPivotal Life SciencesFrazier Healthcare PartnersSeventure PartnersRiverVest Venture PartnersNew Leaf Venture PartnersAlta PartnersPontifax Venture CapitalAmplitude Venture CapitalOkapi Venture CapitalJDRF T1D FundSante VenturesCincyTechRTW Investments L.P.Avedro, Inc.BioInnovation Capital
Firms observed investing alongside Domain Associates, from public investor directories. Shared companies are the overlap with Domain Associates's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.